Investors & Media

Latest Presentations and Publications

Scientific Presentations
Scientific Publications

Latest Presentations

All Presentations

Sangamo Corporate Presentation

Aug 08, 2023

Sangamo Corporate Presentation 4.9 MB

Source ASGCT 2023 Presentation

Engineered Zinc Finger Transcriptional Regulators Specifically Reduce Prion Expression and Extend Survival in an Aggressive Prion Disease Model

May 22, 2023

Engineered Zinc Finger Transcriptional Regulators Specifically Reduce Prion Expression and Extend Survival in an Aggressive Prion Disease Model 6.7 MB

Source ASGCT 2023 Presentation

ZF TF mediated epigenetic repression of SCN9A gene as a therapeutic approach for painful peripheral neuropathies

May 22, 2023

ZF TF mediated epigenetic repression of SCN9A gene as a therapeutic approach for painful peripheral neuropathies 2.7 MB

Source ASGCT 2023 Presentation

Fitness Maturation of Engineered AAV Capsid STAC-102 Enhances Central Nervous System Transduction after CSF Administration in Cynomolgus Macaques

May 19, 2023

Fitness Maturation of Engineered AAV Capsid STAC-102 Enhances Central Nervous System Transduction after CSF Administration in Cynomolgus Macaques 15.5 MB

Source ASGCT 2023 Presentation

Evolution of blood-brain barrier penetrant AAV capsids in non-human primates using a multiplexed transcription dependent capsid engineering platform

May 19, 2023

Evolution of blood-brain barrier penetrant AAV capsids in non-human primates using a multiplexed transcription dependent capsid engineering platform 6.1 MB

Source WORLDSymposium 2023 Presentation

STAAR, a phase 1/2 study of isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease

Feb 22, 2023

STAAR, a phase 1/2 study of isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease 1.9 MB

Source WORLDSymposium 2023 Poster

STAAR, a phase 1/2 study of isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease

Feb 22, 2023

STAAR, a phase 1/2 study of isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease 2.2 MB

Source ASH 2022

Interim Safety and Efficacy Results From a Phase 1/2 Study of Zinc Finger Nuclease-Modified Autologous Hematopoietic Stem Cells for Sickle Cell Disease (PRECIZN-1)

Dec 12, 2022

ASH22: Interim Safety and Efficacy Results From a Phase 1/2 Study of Zinc Finger Nuclease-Modified Autologous Hematopoietic Stem Cells for Sickle Cell Disease (PRECIZN-1) 1.5 MB

Source ASH 2022

Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults With Severe Hemophilia A

Dec 12, 2022

ASH22: Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults With Severe Hemophilia A 294.4 KB

Source PRION 2022

Engineered zinc finger protein transcription factors potently reduce brain PrP expression and extend survival in prion-infected mice

Nov 22, 2022

Engineered zinc finger protein transcription factors potently reduce brain PrP …

Latest Publications

All Presentations

More information is coming soon.